

IBD INNOVATE™

NEW PRODUCT DEVELOPMENT FOR CROHN'S & COLITIS

November 17th and 18th, 2020 • A Virtual Event



CROHN'S & COLITIS 
FOUNDATION



Welcome to IBD INNOVATE 2020!

The Crohn's & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet needs of patients with IBD. In pursuit of this objective, the Foundation launched **IBD Ventures** to directly fund product discovery and development. Building on the launch of IBD Ventures, **IBD INNOVATE: New Product Development for Crohn's & Colitis™** will showcase the current innovative product development pipeline in IBD including novel therapies, diagnostics, devices, and digital health solutions. This third annual conference is an exceptional networking opportunity for all stakeholders dedicated to advancing innovative products to address the critical challenges faced by IBD patients.

Location

Our 2020 program will take place on an interactive virtual conference platform, allowing for live Q&A during research talks and poster sessions. Attendees are also encouraged to take advantage of matchmaking software for 1:1 partnering, “speed dating,” and other informal networking venues..

Information and Registration

<http://www.crohnscolitisfoundation.org/ibd-innovate>

Social Media

Join today's conversation on social media using hashtag #IBDIInnovate

Contact

- **Program-related inquiries:**
entrepreneurship@crohnscolitisfoundation.org
- **Sponsorship-related inquiries:**
Nicholas Roman, nroman@crohnscolitisfoundation.org

AGENDA

Please note that this program is subject to change.

DAY 1, November 17

Welcome and Keynote

11:00 a.m.

Innovation to Bring Solutions to IBD Patients	Andres Hurtado-Lorenzo, Vice President of Translational Research, Crohn's & Colitis Foundation
Emerging Therapies For Treating Intestinal Inflammation	Jo Viney, President, Chief Scientific Officer and Co-Founder, Pandion Therapeutics

Therapeutics I

12:05 p.m.

Exit Strategies: SPNS2 and T cell migration	Susan Schwab, Associate Professor, Skirball Institute of Biomolecular Medicine, New York University School of Medicine
Discovery of a Gut-Restricted Glutamate Carboxypeptidase II (GCPII) inhibitor for IBD	Barbara Slusher, Professor of Neurology, Pharmacology and Molecular Sciences, Psychiatry, Neuroscience, Medicine and Oncology, Johns Hopkins School of Medicine; Director, Johns Hopkins Drug Discovery
Targeting Complimentary Suppressive Cytokines to Inflamed Tissue	John Mumm, Chief Executive Officer, Deka Biosciences

Panel discussion with the three presenters

Devices

1:30 p.m.

Peripheral Focused Ultrasound Stimulation (pFUS): Progress and Updates on Non-Invasive Neuromodulation	Chris Puleo, Senior Biomedical Engineer, GE Research
GI Device Development in a Few Movements	Giovanni Traverso, Assistant Professor, Department of Mechanical Engineering, Massachusetts Institute of Technology and Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School
Ultraviolet light treatment for ulcerative colitis: Light at the end of the tunnel?	Gil Melmed, Director, Inflammatory Bowel Disease Clinical Research at Cedars Sinai

Panel discussion with the three presenters

Stakeholder Keynote

3:00 p.m.

**Crazy Creole Mommy Life/
IBD Moms**

Brooke Abbott, *Patient Thought Leader & Activist*

DAY 2, November 18

Welcome

11:00 a.m.

**Welcome to Day 2 of
IBD Innovate 2020**

Caren Heller, *Chief Scientific Officer, Crohn's & Colitis Foundation*

Poster Session II

11:05 a.m.

Diagnostics and Digital Health

12:30 p.m.

**Do we have reliable
biomarkers to detect
mucosal healing in
ulcerative colitis?**

Avinoam A. Dukler, *Managing Partner & President of Glycominds, LLC*

**Building a prognostic test
for pediatric Crohn's disease**

Andres Hurtado-Lorenzo, *Vice President of Translational Research, Crohn's & Colitis Foundation* and Ciaran Fulton, *Associate Director of Diagnostics, LifeArc*

**The Value of Patient Input:
Improve Patient Outcomes
and Your Bottom Line**

Jen Horonjeff, *Founder and Chief Executive Officer, Savvy Cooperative*

Panel discussion with the three presenters

Therapeutics II

2:00 p.m

Targeting the microbiome with rationally designed consortia in IBD

Rose Szababy, *Director, Immunology, Vedanta Biosciences*

A Platform for Pathobiont and Therapeutic Discovery for Inflammatory Bowel Diseases

Paul Miller, *Chief Scientific Officer, Artizan Biosciences*

How Regenerative Medicine is Changing Inflammatory Bowel Disease

Amy Lightner, *Associate Professor of Surgery Department of Colon and Rectal Surgery, Cleveland Clinic*

Panel discussion with the three presenters

Networking

3:15 p.m

Keynote and Closing

4:00 p.m

Pathway paradigms revealed from the genetics of inflammatory bowel disease

Ramnik Xavier, *Kurt Isselbacher Professor of Medicine, Harvard Medical School; Core Member, Broad Institute; Director, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital*

POSTERS

Organization	Presenter	Poster Title
Microba Life Sciences	Alena Pribyl, <i>Senior Scientist and Research Officer</i>	Improving IBD treatment options through precise microbiome measurement
Tenza	Anik Debnath, <i>Co-Founder & CEO</i>	Engineered Probiotics as Drug Delivery Vehicles for IBD
Coral Genomics	Atray Dixit, <i>CEO</i>	Diversity-oriented precision medicine for IBD
Giiant Pharma	Bernard Cote, <i>Chief Operating Officer</i>	Gut-Restricted PDE4 Inhibitor Prodrugs for the Treatment of IBD
CVasThera	Bruno Le Grand, <i>Chief Executive Officer</i>	
Olink	Chris Bock, <i>Field Application Scientist</i>	Serum protein biomarkers in inflammatory bowel disease and prediction of anti-TNF response
Rise Therapeutics	Christian Furlan Freguia, <i>VP of Research</i>	A Novel Immunologically Engineered Probiotic for the Treatment of Inflammatory Bowel Disease
NiMBAL Health	David Suskind, <i>Professor of Pediatrics, Seattle Children's Hospital and University of Washington, Chief Medical Officer NiMBAL Health</i>	Digital Therapeutics for Inflammatory Bowel Disease
Microbiome Insights Inc.	Erick Cardenas Poire, <i>Senior Director, Bioinformatics</i>	A microbiome-based biomarker for IBD management
Virgo	Matt Schwartz and Ian Strug, <i>Chief Executive Officer and Chief Customer Officer</i>	Integrated Cloud Capture and AI Annotation Tool for Endoscopy Video
Alpha Cancer	Igor Sherman, <i>CEO</i>	Recombinant Human Alfa-fetoprotein —a Novel Therapy for IBD Targeting β 2 Microglobulin
BiomeSense, Inc.	Kevin Honaker, <i>CEO</i>	BiomeSense: Novel Technology for Generating Continuous, Standardized Gut Microbiome Data During IBD-Microbiome Investigations

POSTERS

Organization	Presenter	Poster Title
Patient Authentic	Lilly Stairs, <i>Founder & Principal</i>	Building Authentic Partnerships—Health Tech and Patient Advocacy Organizations
4D Pharma plc	Marsilio Adriani, <i>Principal Scientist</i>	Thetanix: An Oral Single Strain Live Biotherapeutic for the Treatment of IBD
Intact Therapeutics	Navdeep Kaur, <i>Director, R&D</i>	Transforming rectal therapy for ulcerative colitis - Patient perspectives and pilot results of novel thermosensitive topical formulation
Redx Pharma	Peter Bunyard, <i>Head of Fibrosis</i>	The role of ROCK inhibitors in fibrostenosis
RxHealth	Richard Strobridge, <i>Scientific Founder and Board Member</i>	Digital Therapeutics and Monitoring for Healthcare and Life Science
Nori Health	Roeland Pater, <i>Founder and CEO</i>	Personalized digital therapeutic coaching for practical and psychological at-home care
Qu Biologics	Shirin Kalyan, <i>Director of Scientific Innovation</i>	Training innate immune function as a novel approach to treat Crohn's disease: Phase 2 data
Intract Pharma Ltd	Slivia Matiz, <i>Formulation Scientist</i>	Developing Orally Delivered, Gut Tissue Targeted Antibody Therapeutics for GI Autoimmune Diseases
EnLiSense	Sriram Muthukumar, <i>CEO and Co-founder</i>	EnLiSense IBD WATCH: a real-time wearable sweat sensing diagnostics platform
PTM Therapeutics	Tony Liang, <i>VP of Research</i>	hPTM-001: Humanized Antibody Enhancing Mucosal Wound Healing for the Treatment of IBD

:

This conference is sponsored, in part, by:



Our mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

CROHN'S & COLITIS FOUNDATION

733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423